Funding source: This work was supported by program for Changjiang Scholars and Innovative Teams in Universities, Ministry of Education, China (IRT0760).
Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases
Version of Record online: 13 MAR 2013
© 2013 Wiley Periodicals, Inc.
Special Issue: Update on Understanding and Managing Chronic Wounds
Volume 26, Issue 3, pages 263–266, May/June 2013
How to Cite
An, Q., Zhang, L., Zheng, S., Lin, J., Hong, Y., Chen, H.-D. and Gao, X.-H. (2013), Thalidomide improves clinical symptoms of primary cutaneous amyloidosis: report of familiar and sporadic cases. Dermatologic Therapy, 26: 263–266. doi: 10.1111/j.1529-8019.2013.01548.x
Conflict of interest: None.
- Issue online: 6 JUN 2013
- Version of Record online: 13 MAR 2013
- Changjiang Scholars and Innovative Teams in Universities, Ministry of Education, China. Grant Number: IRT0760
Primary cutaneous amyloidosis (PCA), either familial or sporadic, poses a therapeutic challenge. We conducted an open trial using thalidomide to treat three cases of familial and three cases of sporadic PCA, at initial dose of 100 mg/day. Dosage adjustment was made according to improvement of symptoms or patient's own choice. All except one sporadic case experienced moderate to significant relief on the symptoms of itching, over an observational period of 8 weeks by visual analog score (from 8.08 ± 0.88 to 1.60 ± 0.68, on average) as well as clinical amelioration of symptoms. Side effects included fatigue, drowsiness, numbness, and facial and leg edema in some of the patients. From the present observation, it seems that thalidomide is a promising drug to treat PCA.